ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
- DOI
- 10.1016/j.modpat.2023.100273
- Published
- 2023 Oct
- Container
- Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.modpat.2023.100273,
title = {ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.},
author = {McAfee JL and Hoda RS and Hoyle C and McCoy L and Sprague C and Reddy CA and Koyfman SA and Geiger JL and Komforti MK and Griffith CC},
year = {2023},
journal = {Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc},
doi = {10.1016/j.modpat.2023.100273},
url = {https://doi.org/10.1016/j.modpat.2023.100273}
}RIS
TY - JOUR TI - ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy. AU - McAfee JL AU - Hoda RS AU - Hoyle C AU - McCoy L AU - Sprague C AU - Reddy CA AU - Koyfman SA AU - Geiger JL AU - Komforti MK AU - Griffith CC PY - 2023 JO - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc DO - 10.1016/j.modpat.2023.100273 UR - https://doi.org/10.1016/j.modpat.2023.100273 ER -
APA
JL, M., RS, H., C, H., L, M., C, S., CA, R., SA, K., JL, G., MK, K., & CC, G. (2023). ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. https://doi.org/10.1016/j.modpat.2023.100273
Source records
- pubmed · retrieved 2026-11-10T18:04:15.298Z